

## North Yorkshire & York Area Prescribing Committee

**Wednesday 4<sup>th</sup> May 2022**  
**2pm – 4.30pm, virtual meeting via Microsoft Teams**

### Present

Name	Job Title	Organisation	Dec 2021	Feb 2022	Mar 2022	Apr 2022	May 2022
Ken Latta	Head of Medicines Optimisation	North Yorkshire CCG	Y	Y	Y	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire CCG	Y	Y	Y	Apols	Y
TBC	GP	North Yorkshire CCG	X	X	X	X	X
Laura Angus	Head of Medicines Optimisation	Vale of York CCG	Y	Y	Apols	Y	Y
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	Vale of York CCG	Y	Y	Y	Y	Y
Dr William Ovenden	GP	Vale of York CCG	Apols	Y	Y	Y	Apols
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Y	Y	Apols
Dr Ben Walker	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Apols	Apols	Apols	Y
Dr S Brotheridge	Consultant	Harrogate and District NHS Foundation Trust	X	X	X	X	X
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Y
Dr Peter Hall	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y (from 3pm)	Y	Resigned	X
Dr Chris Hayes	Consultant	York & Scarborough Teaching Hospitals NHS Foundation Trust	X	Y	X	Y	X
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Y	Y	Laura Tweddle	Y
	Consultant	South Tees Hospitals NHS Foundation Trust	X	X	X	X	X
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Y (till 3.30pm)	Chris Williams	Y	Y
Shona McIlrae	Consultant Psychiatrist	Tees, Esk and Wear Valleys NHS Foundation Trust	Gena Hearnshaw	X	X	X	X
Angela Hall	Public Health representative	North Yorkshire County Council	Kurt Ramsden	Kurt Ramsden	Apols	Apols	X
Anita Dobson	Public Health representative	City of York Council	Y	Apols	Y	Y (from 3pm)	Y (till 3.30pm)
Alison Levin	Finance representative	North Yorkshire CCG	Kathryn Shaw-Wright	Kathryn Shaw-Wright	Kathryn Shaw-Wright	Apols	Kathryn Shaw-Wright
Steve Jordan (till Jan 2022)	Contracting representative	North Yorkshire CCG	Apols	X	X	X	X
Hazel Mitford	Lay/patient representative		Y	Y	Y	Y	Y
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	Y	Y	Y	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire CCG	Y	Y	Y	Y	Y
Faisal Majothi	Medicines Optimisation Pharmacist	Vale of York CCG	Y	Y	Y	Y	Y
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS	Y	Y	Y	Y	Y

		Foundation Trust					
Sara Abbas-Llewelyn / Emily Parkes	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	X	X	X	X	X
Ian Dean	LPC Representative		Y	Y (till 3pm)	Y	Y	Y
Dr Sally Tyrer	LMC Representative		Apols	Apols	X	X	Apols
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	X	X	Y	X	Y
Chris Williams	Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	X	X	Y	X	X

### **In attendance**

Barry Hogan – RDTTC – sharing papers on screen via MS Teams

The meeting was quorate with 12 out of 17 currently appointed voting members in attendance present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision making. Discretion should be used when discussing meetings with non-attendees and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

### **Part 1**

#### **1. Apologies for absence and Quoracy Check**

William Ovenden, Kate Woodrow, Sally Tyrer

#### **2. Declarations of Interest**

##### **Declarations of interest:**

*The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.*

*Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.*

##### **Declarations of interest from today's meeting:**

*Shaun O'Connell - undertaken a non-promotional, non-product survey for Novo Nordisk recently.*

#### **3. Minutes of Previous APC & Decision Summary of Meeting Held 2<sup>nd</sup> March 2022 (+outcome of VoY CCG exec)**

The minutes of the April 2022 APC were approved as true and accurate record subject to some minor spelling and grammar being updated.

Item 22 – confirmed that South Tees Trust is the provider of North Yorkshire weight management service.

It was confirmed that the VoY CCG CE committee has approved the recommendations from the April 2022 APC Meeting.

It was confirmed that NY CCG has approved the recommendations from April 2022 APC meeting that were above the financial delegated authority of the APC.

**4. Matters Arising Not On The Agenda & Declarations of AOB**

Nil

**5. Action Log**

Formulary NICE TAs and MHRA Drug Safety Update – February 2022 – plus lurasidone, liothyronine caps, empagliflozin and dapagliflozin, glaucoma pathway, migraine pathway JEC/SAL to update the formulary websites now recommendations approved by NY and VoY CCG.

Terms of Reference – updated April 2022

RDTc made amendment to clarify process for urgent requests. Completed – ITEM NOW CLOSED.

Oestriol 0.03mg pessary (Imvaggis®)

The APC discussed this formulary application received from HDFT.

It was noted that creams should remain the 1<sup>st</sup> line treatment option as cheaper than pessaries.

After confirmation of support for the application from clinicians at YSHFT it was agreed to approve as a GREEN drug as more cost-effective alternative to Vagifem® for local treatment of vaginal symptoms of estrogen deficiency in postmenopausal women.

**ACTION:**

- **JC/SAL to update the formulary websites once approved by VoY CCG.**

Phosphate Binders – review of RAG status

Work still in progress.

County Durham & Tees Valley APC Cinacalcet SCG

RDTc still to be discussed with /KL differences in monitoring in Cinacalcet SCG between CD&T and NY&Y outside of the meeting.

**Outstanding Actions from Previous APC Meetings**

Formulary status of alcohol dependence drugs for VoY CCG - Acamprosate and Disulfiram

Work still in progress

TEWV Safe transfer of prescribing guidance – updated

Link to TEWV Safe transfer of prescribing guidance been added to formulary. ITEM NOW CLOSED.

TEWV Risperidone LAI SCG

JEC/SAL to update the formulary websites once approved by VoY CCG – still to be actioned as not updated on TEWV website.

TEWV Guanfacine SCG

Link now updated on the formulary websites. ITEM NOW CLOSED.

TEWV Anxiety Guidelines – updated

JEC/SAL to update the formulary websites once approved by VoY CCG – still to be actioned as not updated on TEWV website.

CR to add link to TEWV Anxiety Guidelines on APC website – still to be actioned as not updated on TEWV website.

**Historic Actions Carried Over from June 2021 MCC meeting**

Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring 16 December 2020 - Updated RCOphth guidelines

Awaiting final guidance and SCG template from RMOC.

Melatonin YSTHFT Shared care

Still to progress paper due to current work pressures.

**Part 2 – Governance**

6. Nil this month.

**Part 3 – Mental Health**

**7. TEWV Drug & Therapeutics Committee Feedback – Mar 2022**

RM presented to the APC a briefing report highlighting the main issues discussed at the recent TEWV D&T.

**8. TEWV Bipolar disorder under 18s prescribing tips FINAL DRAFT for APCs**

This a new document from TEWV largely intended for internal use within TEWV and was presented to the APC for comment.

The APC agreed it was useful document and noted it matches NICE guidance. It was approved by the APC subject to the formulary/RAG status of each of the included drugs being made clearer.

**9. Dementia Care Pathway AChEI decision aid**

An updated version of this document from TEWV was presented to the APC. It was noted that only minor changes have been made.

It was confirmed that memory clinics do assess anticholinergic burden when patients are referred to them.

It was felt that issues around transfer of prescribing in Harrogate were now largely resolved but any continuing issues should be picked up with the NY Medicines Management Team.

The APC approved the document subject to highlighting the high cost of donepezil orodispersible tablets and emphasising that they should only be used when clinically indicated.

**Part 4 – Formulary Issues**

**10. Appeals Against Previous APC Decisions**

None received.

**11. Formulary NICE TAs and MHRA Drug Safety Update – March 2022**

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
- TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
- TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
- HST18: Atidarsagene autotemcel for treating metachromatic leukodystrophy

The drugs in the following TAs to be reflected in the formulary as NOT APPROVED for this indication in the relevant chapters with links to the TAs:

- TA774: Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)
- TA782: Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)

All of the above TAs are NHSE-commissioned, therefore would have no cost impact to CCGs.

The drugs in the following CCG Commissioned TAs to be reflected in the formulary as NOT APPROVED for this indication in the relevant chapters with links to the TAs:

- TA776: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
- TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea

### **Medicines Safety (MHRA drug safety update – March 2022)**

The group noted the drug safety updates for March 2022. The links are to be added to the relevant sections of the formulary.

#### **ACTION:**

- **JC/SAL to update the formulary websites once approved by VoY/NY CCG.**

The APC also discussed the updated to NICE guidance around glucose monitoring that were published on the 31<sup>st</sup> March 2022. It was noted that work is underway in Humber, Coast and Vale to produce an updated Y&H policy on CGM and Flash Glucose Monitoring. The financial implications of these updated NICE guidelines were noted, as well as implementation issues as they will be drive for initiation of Flash in primary care rather than secondary care, particularly for type 2 diabetes patients.

NG91 – Otitis Media (updated) - The APC agreed to consider adding phenazone + lidocaine ear drops to the formulary when the updated RSS guidance comes to APC for approval.

It was also discussed and agreed that Trusts would bring any therapeutic pathway changes identified for non-NSHE funded NICE TA drugs to the APC as a short report/list routinely every month. The APC will then ensure there is not duplication of effort across the Trusts, and we have a unified therapeutic pathway across the patch.

## **12. Other Formulary Issues**

- Nil this month.

## **13. New Drug Applications**

### Lyumjev® Insulin

The APC discussed the formulary application received from YSHFT. It was noted that is already on the Harrogate formulary.

An RDTC New Drug Evaluation on Lymujev® was presented to the APC to support the APC in its decision making.

A number of points were raised in the discussions:

- Why are both Fiasp® and Lyumjev® needed on the formulary?
- What advantages in clinical practice does Lyumjev® have over Fiasp®, and over Humalog®?
- Should Humalog® biosimilars not be used more?
- Is it more cost-effective that other options for a specific group of patients?
- Comes in two strengths which may cause confusion.
- Not licensed in children unlike Fisap®.
- Lymujev® Kwipen Junior whilst offering 0.5-unit dosing unlike Fiasp® might be misleading as not licensed in children.

After discussion it was agreed to defer a decision to the next APC to get a greater understanding on place in therapy, costs versus biosimilar Humalog®, and need for both Fiasp® and Lyumjev® to be on formulary.

**ACTION:**

- **JC to discuss with YSHFT Diabetes Team re place in therapy, costs versus biosimilar Humalog®, and need for both Fiasp® and Lyumjev® to be on formulary.**

**14. Compassionate Use/Free of Charge Scheme Requests**

Nil this month.

**15. Leeds/West Yorkshire APC Update**

February 2022 West Yorkshire APC minutes circulated for information to APC members.

**16. RMOC Update**

Nil this month.

**Part 5 – Shared Care and Guidelines (non-Mental Health)**

**17. Shared Care Guidelines for Approval**

Nil this month.

**18. Dosulepin Position Statement**

A draft APC position statement on dosulepin was presented to and approved by the APC. Approved to support deprescribing of dosulepin locally in line with NHSE guidance on items of low clinical value.

It was noted that the NY&Y Medicines Safety Group would look at this as a monthly topic to try and address those GP practices which continue to prescribe.

**19. Clinically Assisted Hydration in Palliative Care Policy V5 Feb 22 with highlights**

A new combined policy from HDFT and YSHFT was presented to and approved by the APC. It was noted that the two Trust still use different routes of supply and have their own fluid charts. It was felt that it was not possible at this stage to align the fluid charts.

**Part 6 – Other Items of Business**

**22.** Nil this month.

**Part 7 – Standing Items (for information only)**

**23. TEWV D&T Minutes – March 2022**

Not yet available.

**24. York & Scarborough Trust Drug and Therapeutics Committee Minutes – January & March 2022**

Circulated for information.

**25. Harrogate Trust Medicines and Therapeutics Group Minutes – March 2022**

Not yet available.

**26. Hull and East Riding Prescribing Committee (HERPC) minutes – since November 2021**

Not yet available.

**27. County Durham & Tees Valley APC Minutes – March 2022**

Not yet available.

**26. West Yorkshire & Harrogate ICS APC Minutes – February 2022**

Circulated for information.

**27. NE Lincolnshire APC Minutes – February 2022**

Circulated for information.

**28. RDTC Monthly Horizon scanning – April 2022**

Circulated for information.

**Any Other Business**

APC Governance post 1st July 2022

Noted that accountability and delegated authority arrangements for the APC when the ICS comes legally into being on 1st July 2022 are still to be confirmed.

**ACTION:**

- **SOC/TR to discuss with the ICS the accountability and delegated authority arrangements for the APC when the ICS comes legally into being on 1st July 2022**

DOACs for AF

Noted that updated YSHFT guidance on DOAC choice was approved at their last D&T. They have been using edoxaban 1<sup>st</sup> line for a number of years.

The wider NY&Y position of choice of DOACs for AF is still being discussed and a proposal/position statement will come to a future APC for approval.

Fentanyl patches for fractured neck of femur (SP)

Noted YSHFT have approved a new analgesia pathway. The plan is to use morphine sulphate or oxycodone immediate release with the aim of being able to wean patients off opioids before going home. This now needs to be communicated to primary care so if patients are potentially sent home with strong opioids, they ensure they do not stay on these long term. The plan would be if a patient did need to go home with an opioid it would be a “when required” opioid and not a regular one.

HDFT Alcohol Withdrawal Policy (updated)

Noted that HDFT have approved an updated Alcohol Withdrawal Policy which differs from NICE with dosing of chlordiazepoxide based on alcohol use and not agitation score. It was suggested that this be referred to the NE&Y Regional Chief Pharmacist for regional adoption to be considered possibly via RMOC.

**Date and time of next meeting**

Wednesday 6<sup>th</sup> July 2022, 2pm – 4.30pm, Virtual Meeting via Microsoft Teams  
(Note June 2022 meeting cancelled)